[go: up one dir, main page]

DK2506712T3 - MORPHINAND DERIVATIVES FOR TREATMENT OF Drug Overdose - Google Patents

MORPHINAND DERIVATIVES FOR TREATMENT OF Drug Overdose Download PDF

Info

Publication number
DK2506712T3
DK2506712T3 DK10834900.2T DK10834900T DK2506712T3 DK 2506712 T3 DK2506712 T3 DK 2506712T3 DK 10834900 T DK10834900 T DK 10834900T DK 2506712 T3 DK2506712 T3 DK 2506712T3
Authority
DK
Denmark
Prior art keywords
morphinand
derivatives
treatment
drug overdose
overdose
Prior art date
Application number
DK10834900.2T
Other languages
Danish (da)
Inventor
Bernard Silverman
Fen-Ni Fu
Chengyun Guo
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Application granted granted Critical
Publication of DK2506712T3 publication Critical patent/DK2506712T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK10834900.2T 2009-12-04 2010-10-13 MORPHINAND DERIVATIVES FOR TREATMENT OF Drug Overdose DK2506712T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26688109P 2009-12-04 2009-12-04
PCT/US2010/052437 WO2011068594A1 (en) 2009-12-04 2010-10-13 Morphinan derivatives for the treatment of drug overdose

Publications (1)

Publication Number Publication Date
DK2506712T3 true DK2506712T3 (en) 2019-06-03

Family

ID=44082631

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10834900.2T DK2506712T3 (en) 2009-12-04 2010-10-13 MORPHINAND DERIVATIVES FOR TREATMENT OF Drug Overdose

Country Status (20)

Country Link
US (4) US9119848B2 (en)
EP (2) EP3569234A1 (en)
JP (2) JP5691042B2 (en)
AU (1) AU2010326676B2 (en)
CA (1) CA2782529C (en)
CY (1) CY1121646T1 (en)
DK (1) DK2506712T3 (en)
ES (1) ES2729679T3 (en)
HR (1) HRP20191029T1 (en)
HU (1) HUE043963T2 (en)
LT (1) LT2506712T (en)
ME (1) ME03468B (en)
NZ (1) NZ600379A (en)
PL (1) PL2506712T3 (en)
PT (1) PT2506712T (en)
RS (1) RS58894B1 (en)
SI (1) SI2506712T1 (en)
SM (1) SMT201900357T1 (en)
TR (1) TR201908514T4 (en)
WO (1) WO2011068594A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2477627B1 (en) * 2009-09-18 2018-08-15 Merck Sharp & Dohme Corp. Use of opioid receptor antagonist for gastrointestinal tract disorders
SI2506712T1 (en) * 2009-12-04 2019-06-28 Alkermes Pharma Ireland Limited, Morphinan derivatives for the treatment of drug overdose
DK2608670T3 (en) 2010-08-23 2019-02-11 Alkermes Pharma Ireland Ltd METHOD OF TREATING ANTI-SOCIETY-INDICATED WEIGHT RISE
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) * 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
HUE044957T2 (en) * 2011-12-15 2019-11-28 Alkermes Pharma Ireland Ltd Samidorphan (alks 33) in combination with opioid agonists
EP3415148A1 (en) * 2011-12-15 2018-12-19 Alkermes Pharma Ireland Limited Compositions of buprenorphine and mu-opioid receptor antagonists
US10195191B2 (en) 2011-12-15 2019-02-05 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
NZ631018A (en) * 2013-05-24 2017-12-22 Alkermes Pharma Ireland Ltd Morphan and morphinan analogues, and methods of use
WO2014190271A2 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limted Methods for treating depressive symptoms
US10550088B2 (en) 2013-12-27 2020-02-04 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
US10202382B2 (en) * 2014-06-13 2019-02-12 Purdue Pharma L.P. Azamorphinan derivatives and use thereof
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
US9763572B2 (en) * 2015-02-17 2017-09-19 Children's Hospital Medical Center Quantitative pupillometry as a bedside predictor of postoperative respiratory depression
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
CN118598813B (en) * 2024-08-08 2024-10-29 山东齐都药业有限公司 L-malic acid salsa Mi Duofen and preparation method thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES252980A1 (en) 1958-10-30 1960-11-01 Boehringer Sohn Ingelheim Normorphine derivatives
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
CH581624A5 (en) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
DE2254298A1 (en) 1972-11-06 1974-05-16 Boehringer Sohn Ingelheim Heteroarylmethyl-normorphines prepn - by alkylation of normorphine etc., antidotes for opiate poisoning
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US4127577A (en) 1975-11-24 1978-11-28 Sterling Drug Inc. Aminomethanobenzazocine process
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4161597A (en) 1976-12-20 1979-07-17 Research Corporation N-alkyl-14-hydroxymorphinans and derivatives
US4100228A (en) 1977-04-04 1978-07-11 The Dow Chemical Company Transparent impact styrene polymer structure
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4373139A (en) 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
FR2514644A1 (en) 1981-10-19 1983-04-22 Sanofi Sa PHARMACEUTICAL COMPOSITION WITH PERIPHERAL ANTAGONIST ACTION OF OPIACES
US4374139A (en) 1981-11-09 1983-02-15 Hoffmann-La Roche Inc. Levorotatory N-substituted acylmorphinans useful as analgesic agents
DE3220831A1 (en) 1982-06-03 1983-12-08 Boehringer Ingelheim KG, 6507 Ingelheim N- (2-METHOXYETHYL) -NOROXYMORPHONE, ITS ACID ADDITION SALTS, MEDICINAL PRODUCTS CONTAINING THEM AND METHOD FOR THE PRODUCTION THEREOF
US4451470A (en) 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US4929622A (en) 1987-09-24 1990-05-29 Hoechst-Roussel Pharmaceuticals, Inc. 2,6-Methanopyrrolo-3-benzazocines
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5250542A (en) 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5270328A (en) 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5258386A (en) 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (en) 1991-12-18 1991-12-18 Wikstroem Haakan ARYL-TRIFLATES AND RELATED COMPOUNDS
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
US5434171A (en) 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
HUP9900974A3 (en) 1996-01-10 2000-09-28 Smithkline Beecham Spa Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
GB9616253D0 (en) 1996-08-01 1996-09-11 Johnson Matthey Plc Preparation of narcotic analgesics
ES2121553B1 (en) 1996-12-23 1999-06-16 Univ Santiago Compostela NEW MORPHINIC ENDOPEROXIDES FUNCTIONALIZED IN POSITIONS C-6 AND C-14 OF RING C AND PROCEDURE FOR THEIR OBTAINING.
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
JP4890710B2 (en) 1999-08-13 2012-03-07 サザン・リサーチ・インスティテュート Pyridomorphinans, thienomorphinans and their use
NZ518562A (en) 1999-11-29 2005-04-29 Adolor Corp Novel methods and compositions involving opioids and antagonists thereof
AU2002227135B2 (en) 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
SI1485051T1 (en) 2002-03-20 2008-10-31 Euro Celtique Sa Method of administering buprenorphine to treat depression
AU2003239389A1 (en) 2002-05-30 2003-12-19 Eli Lilly And Company Opioid receptor antagonists
WO2004005924A1 (en) 2002-07-03 2004-01-15 Spinelix 3d microarray
DE10229842A1 (en) 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinane derivatives and their quaternary ammonium salts substituted in position 14, production process and use
WO2004007449A1 (en) 2002-07-16 2004-01-22 Rensselaer Polytechnic Institute Process for conversion of phenols to carboxamides via the succinimide esters
US7271173B2 (en) 2002-11-18 2007-09-18 The Mclean Hospital Corporation Mixed kappa/mu opioids and uses thereof
WO2004071423A2 (en) * 2003-02-05 2004-08-26 Euro-Celtique S.A. Methods of administering opioid antagonists and compositions thereof
ES2303085T3 (en) 2003-04-29 2008-08-01 Orexigen Therapeutics, Inc. COMPOSITIONS AFFECTING LOSS OF WEIGHT.
WO2005101979A2 (en) 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
AU2005245403B2 (en) 2004-05-14 2012-04-19 Janssen Pharmaceutica N.V. Carboxamido opioid compounds
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
WO2006052710A1 (en) 2004-11-05 2006-05-18 Rensselaer Polytechnic Institute 4-hydroxybenzomorphans
WO2006096626A2 (en) 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US7557119B2 (en) 2005-07-21 2009-07-07 Rensselaer Polytechnic Institute Large substituent, non-phenolic opioids
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
US8551986B2 (en) 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
EP1983991A2 (en) * 2006-02-01 2008-10-29 Alkermes, Inc. Methods of treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers
CA2663909A1 (en) 2006-09-20 2008-03-27 Mallinckrodt Inc. Preparation of substituted morphinan-6-ones and salts and intermediates thereof
EP2099456A2 (en) 2006-11-22 2009-09-16 Progenics Pharmaceuticals, Inc. N-oxides of 4,5-epoxy-morphinanium analogs
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
PL2134330T3 (en) 2007-03-19 2013-10-31 Acadia Pharm Inc Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
AU2008255049A1 (en) 2007-05-16 2008-11-27 Rensselaer Polytechnic Institute Fused-ring heterocycle opioids
CA2694497C (en) 2007-08-09 2016-07-12 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
TR201809734T4 (en) * 2008-02-14 2018-07-23 Alkermes Inc Selective opioid compounds.
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
AU2009274147B2 (en) 2008-07-21 2014-09-04 Rensselaer Polytechnic Institute Large substituent, non-phenolic amine opioids
JP5555890B2 (en) * 2009-03-19 2014-07-23 アルカーメス ファーマ アイルランド リミテッド Morphinan derivatives with high oral bioavailability
WO2010141666A2 (en) 2009-06-04 2010-12-09 The General Hospital Corporation Modulating endogenous beta-endorphin levels
SI2506712T1 (en) 2009-12-04 2019-06-28 Alkermes Pharma Ireland Limited, Morphinan derivatives for the treatment of drug overdose
AU2011232628B2 (en) 2010-03-22 2015-04-09 Rensselaer Polytechnic Institute Morphinane derivatives containing a carboxamide group as opioid receptor ligands
ES2708726T3 (en) 2010-07-08 2019-04-10 Alkermes Pharma Ireland Ltd Process for the synthesis of substituted morphinan
JP2013532731A (en) 2010-08-04 2013-08-19 マリンクロッド エルエルシー N-demethylation of 6-ketomorphinan
DK2608670T3 (en) 2010-08-23 2019-02-11 Alkermes Pharma Ireland Ltd METHOD OF TREATING ANTI-SOCIETY-INDICATED WEIGHT RISE
WO2012088494A1 (en) 2010-12-23 2012-06-28 Pheonix Pharmalabs, Inc. Novel morphinans useful as analgesics
EP3415148A1 (en) 2011-12-15 2018-12-19 Alkermes Pharma Ireland Limited Compositions of buprenorphine and mu-opioid receptor antagonists
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations

Also Published As

Publication number Publication date
AU2010326676A1 (en) 2012-06-21
SMT201900357T1 (en) 2019-07-11
US20160051535A1 (en) 2016-02-25
AU2010326676B2 (en) 2013-03-14
JP2015038139A (en) 2015-02-26
TR201908514T4 (en) 2019-07-22
PT2506712T (en) 2019-05-31
SI2506712T1 (en) 2019-06-28
EP2506712A1 (en) 2012-10-10
ES2729679T3 (en) 2019-11-05
CA2782529C (en) 2015-05-26
US20170333422A1 (en) 2017-11-23
JP2013512901A (en) 2013-04-18
WO2011068594A1 (en) 2011-06-09
HUE043963T2 (en) 2019-09-30
ME03468B (en) 2020-01-20
EP3569234A1 (en) 2019-11-20
US9119848B2 (en) 2015-09-01
HRP20191029T1 (en) 2019-09-20
EP2506712B8 (en) 2019-06-19
NZ600379A (en) 2014-05-30
EP2506712A4 (en) 2013-07-10
US20110136848A1 (en) 2011-06-09
JP5691042B2 (en) 2015-04-01
US20200345718A1 (en) 2020-11-05
LT2506712T (en) 2019-06-25
CY1121646T1 (en) 2020-07-31
EP2506712B1 (en) 2019-03-27
CA2782529A1 (en) 2011-06-09
JP6216305B2 (en) 2017-10-18
RS58894B1 (en) 2019-08-30
AU2010326676A2 (en) 2012-08-30
PL2506712T3 (en) 2019-09-30

Similar Documents

Publication Publication Date Title
DK2506712T3 (en) MORPHINAND DERIVATIVES FOR TREATMENT OF Drug Overdose
CY2020008I1 (en) PHARMACEUTICAL FORMS OF DISTROMAT TABLET
DK2558105T3 (en) BARDOXOLONMETHYL FOR TREATMENT OF OBESE
DK3653223T3 (en) UNIT FOR ORAL DELIVERY OF THERAPEUTIC COMPOUNDS
DK3461478T3 (en) SYNCABLE UNIT FOR DELIVERY OF MEDICINES
BR112012011902A2 (en) pharmaceutical capsule
HRP20150029T1 (en) PHARMACEUTICAL PREPARATION FOR TREATMENT OF METABOLIC SYNDROME
DK3251678T3 (en) BENZOXABOROL DERIVATIVES FOR THE TREATMENT OF BACTERIA INFECTIONS
IT1394860B1 (en) PHARMACEUTICAL COMPOUNDS
HUE056843T2 (en) Infusion of drugs
DK3527241T3 (en) DEVICE FOR ADMINISTRATION OF MEDICINAL PRODUCTS
DK3192520T3 (en) THERAPEUTIC MEASURES FOR REDUCING THE LEVELS OF PARATHYREOIDEAHORMONE
DK2872497T4 (en) CHROMANYL DERIVATIVES FOR TREATMENT OF MITOCONDAL DISEASE
EP2442821A4 (en) SAFE ADMINISTRATION OF DESMOPRESSINE
LT3222272T (en) PHARMACEUTICAL COMPOSITION OF CARBETOCINE
DK3603704T3 (en) ADMINISTRATION OF MEDICATION
DK2451482T3 (en) COMBINATION THERAPY FOR THE TREATMENT OF DIABETES
EP2720699A4 (en) ADMINISTRATION OF BENZODIAZEPINE
DK2701733T3 (en) CONNECTIONS FOR TREATMENT OF NEUROPSYCIATRIC DISORDERS
SI2582366T1 (en) A pharmaceutical combination for the treatment of pain
BRPI1014688A2 (en) therapeutic applications of quinazolinadione derivatives
DK3884947T3 (en) ENHANCEMENT OF DRUG BIOAVAILABILITY IN NALTREXONE THERAPY
HRP20180567T1 (en) PHARMACEUTICAL PREPARATION OF OMEPRAZOL
IT1393930B1 (en) PHARMACEUTICAL COMPOUNDS
DK2501381T3 (en) TREATMENT OF ATRIE FLIMS